| 319.44 Delayed Data As of 4:00pm ET |  +2.71 / +0.86%Today’s Change | 249.17 Today|||52-Week Range 388.67 | +0.27% Year-to-Date |
| Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis Dec 07 / Zacks.com - Paid Partner Content | AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018 Dec 03 / Zacks.com - Paid Partner Content |
| FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Dec 04 / Zacks.com - Paid Partner Content | Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma Nov 29 / Zacks.com - Paid Partner Content |
| Previous close | 316.73 |
| Today’s open | 317.94 |
| Day’s range | 310.99 - 321.11 |
| Volume | 928,034 |
| Average volume (3 months) | 1,207,005 |
| Market cap | $63.6B |
| Earnings growth (last year) | -29.57% |
| Earnings growth (this year) | +18.41% |
| Earnings growth (next 5 years) | +6.46% |
| Revenue growth (last year) | +7.81% |
| P/E ratio | 20.7 |
| Price/Sales | 6.17 |
| Price/Book | 5.29 |
| Today’s change | Today’s % change | |
|---|---|---|
| ILMNIllumina Inc | +1.64 | +0.51% |
| GILDGilead Sciences | -0.66 | -0.97% |
| TLRYTilray Inc | -3.11 | -3.10% |
| NBIXNeurocrine Bioscienc... | +1.63 | +1.94% |
| Next reporting date | January 30, 2019 |
| EPS forecast (this quarter) | $6.73 |
| Annual revenue (last year) | $11.0B |
| Annual profit (last year) | $2.5B |
| Net profit margin | 23.10% |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Michel Vounatsos |
Chief Financial Officer & Executive Vice President Jeffrey D. Capello |
Corporate headquarters Cambridge, Massachusetts |
